Pliant Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company presented promising early clinical data for its integrin-blocking oncology program, with durable responses and a robust biomarker strategy. Preclinical siRNA delivery efforts are advancing, with muscle-targeting studies in primates and data expected this year. Key clinical and platform milestones are anticipated in 2026 and 2027.
-
Transitioned focus to oncology with lead integrin-targeting program PLN-101095, showing promising phase I results and a strong safety profile. Phase Ib study starts in Q2, with a robust cash position supporting aggressive development and ongoing evaluation of new pipeline and partnering opportunities.
Fiscal Year 2025
-
Durable responses and a favorable safety profile were observed in the phase 1 study, prompting advancement to a phase 1b trial in non-small cell lung cancer and other tumors. The pipeline will expand with new programs by 2026, supported by a strong cash position through 2028.
-
Bexotegrast is advancing through phase IIb/III trials for IPF and will soon enter pivotal PPF studies, showing strong efficacy, safety, and unique symptomatic benefits. Market growth is expected from increased treatment rates and new indications, with competitive differentiation based on safety and disease-modifying effects.
Fiscal Year 2024
-
BEACON-IPF study enrollment is on track for Q1 2025 completion, with top-line data expected mid-2026. The study uses global, seamless design, stratifies by background therapy, and focuses on FVC and anti-fibrotic biomarkers. Cash runway extends through 2026.
-
Bexotegrast is advancing in global phase II-B/III trials for IPF, showing durable efficacy and strong safety. The company is also exploring PPF and PSC indications, with early-stage oncology and DMD assets positioned for partnerships. Cash runway extends into 2027.
-
The team highlighted strong progress in developing bexotegrast for IPF, with robust safety and efficacy signals and a pivotal program designed to accelerate regulatory timelines. Financial resources are sufficient to reach key milestones, and the company is exploring additional business development opportunities.
-
The company is advancing bexotograst for fibrotic lung diseases, with strong safety and efficacy data supporting expansion into broader ILD indications. The BEACON-IPF trial is accelerating timelines, and partnering opportunities exist for oncology and PSC programs.
-
The company highlighted strong phase II-A results for Bexotegrast in IPF, including safety, efficacy, and biomarker improvements, and detailed a robust pipeline with expansion plans into other fibrotic diseases. The pivotal BEACON-IPF trial is on track, supported by a solid cash position.
-
Bexotograst shows strong safety and efficacy in IPF, with dose-dependent improvements in lung function and fibrosis. The BEACON-IPF trial is on track, targeting broad applicability and market growth, while expansion into other fibrotic diseases and lifecycle management are key strategic priorities.
-
Bexotegrast leads a robust pipeline with a seamless phase IIb/III IPF trial, aiming for broad patient coverage and expedited timelines. Strong safety, promising efficacy, and positive physician feedback support its potential, while oncology and PSC programs advance alongside strategic business development.